Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

Angiogenesis & VEGF / VEGFR2 Mechanism Map

Angiogenesis — the formation of new blood vessels — is a central element of wound healing and a major axis of action claimed for tissue-repair peptides. This page covers the pathway, the peptides invoked, the evidence base, and the off-target concern that comes with promoting vascular growth.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

Pathway background

Angiogenesis is the process by which new capillaries sprout from existing vasculature. It is essential for wound healing, embryonic development, and exercise-induced tissue adaptation — and a known contributor to tumour growth and diabetic retinopathy. Vascular endothelial growth factor (VEGF-A) is the dominant pro-angiogenic signalling molecule; its principal receptor on endothelial cells is VEGFR2 (KDR).

VEGFR2 activation drives endothelial proliferation, migration, sprouting, and tube formation, and also modulates vascular permeability. The nitric oxide (NO) system acts as a downstream and parallel modulator — endothelial nitric oxide synthase (eNOS) is activated by VEGFR2 signalling, and NO in turn relaxes vascular smooth muscle and recruits further angiogenic signalling. Several tissue-repair peptide claims invoke this VEGFR2 / NO axis as their mechanism of action.

The pathway in steps

  1. Hypoxia or tissue injury → HIF-1α stabilisation in cells.
  2. HIF-1α → transcription of VEGF and related growth factors.
  3. VEGF binds VEGFR2 on endothelial cells.
  4. VEGFR2 activation drives endothelial proliferation, migration, sprouting and tube formation.
  5. Nitric-oxide signalling co-modulates vascular tone and permeability.
  6. Mature capillary network is established; tissue perfusion improves.

Peptide interactions claimed in the literature

  • BPC-157 — claimed to up-regulate VEGFR2 expression and to modulate the nitric-oxide system, accelerating early angiogenic responses in rodent injury models. The Sikiric-lab body of work dominates this evidence base. See our Sikiric lab citation map.
  • TB-500 — synthetic fragment of thymosin β4; claimed to promote endothelial cell migration and tube formation in vitro, with rodent tissue-repair signal in tendon, ligament and cardiac models.
  • GHK-Cu — copper tripeptide; claimed to modulate angiogenic signalling and to support the collagen remodelling phase of repair through MMP modulation.

Evidence status

Human evidence: minimal direct human RCT data for any of these peptides in their claimed tissue-repair indications. Most published human data is in unrelated contexts (e.g. BPC-157 GI work) or is small-trial preliminary.

Preclinical evidence: substantial for all three. BPC-157 in particular has dozens of rodent tendon and gut-injury papers. The translation problem is the standard one — rodent VEGFR2 pharmacology does not reliably translate to human clinical outcomes. See animal vs human evidence.

Replication caveat: the BPC-157 angiogenic literature is heavily concentrated in a small number of laboratories. Independent replication outside the Sikiric group remains limited. See negative & null evidence.

The off-target concern

Pro-angiogenic signalling is not benign. VEGFR2 activation is implicated in tumour vascularisation, in proliferative diabetic retinopathy, and in certain inflammatory states. The clinical drug development community has invested heavily in anti-angiogenic agents (bevacizumab, ranibizumab, kinase inhibitors targeting VEGFR2) for precisely these reasons. Active or recent malignancy is a theoretically serious contraindication for any pro-angiogenic peptide, even at the research-evidence stage.

Related stacks and combinations